FIELD: medicine.
SUBSTANCE: described solid pharmaceutical formulation for oral introduction contains granulated material consisting of 42-ester of rapamicine with 3-hydroxy-2-(hydroxymethyl)-2-methyl propionic acid in amount from approximately 1 weight % to approximately 30 weight %, water-soluble polymer, such as polyvinylpyrrolidone (PVP) in amount from approximately 1 weight % to approximately 40 weight %, surface-active substance, such as sodium lauryl sulphate in amount from approximately 1 weight % to approximately 8 weight %, antioxidant in amount from approximately from 0.001 weight % to 3 weight % and pH regulating agent.
EFFECT: provides high bioavailability of non-micronised composition.
16 cl, 3 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TUMOR COMPOSITIONS CONTAINING RAPAMICINE DERIVATIVE AND AROMATASE INHIBITOR | 2004 |
|
RU2355399C2 |
| CCI-779 FOR AMPHICYTE LYMPHOMA TREATMENT | 2004 |
|
RU2358731C2 |
| LYOPHILISED COMPOSITIONS CCI-779 | 2004 |
|
RU2345772C2 |
| RAPAMYCINE HYDROXY ETHERS-CONTAINING PARENTERAL COMPOSITIONS | 2003 |
|
RU2344821C2 |
| AMORPHOUS 42-ESTER OF RAPAMYCIN AND 3-HYDROXY-2(HYDROXYMETHYL)-2-METHYLPROPANOIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAING IT | 2004 |
|
RU2345999C2 |
| REGIOSPECIFIC SYNTHESIS OF RAPAMYCIN 42-ESTER DERIVATIVES | 2005 |
|
RU2387657C2 |
| ANTICANCER ACTIVITY OF CCI-779 IN PAPILLARY RENAL CELL CARCINOMA | 2008 |
|
RU2501559C2 |
| ANTICANCER COMBINATIONS OF CCI-779 AND RITUXIMAB | 2005 |
|
RU2389508C2 |
| REGIOSELECTIVE CCI-779 SYNTHESIS | 2004 |
|
RU2339639C2 |
| PHARMACOLOGICAL COMPOSITION WITH SWELLING COATING | 2004 |
|
RU2375048C2 |
